Teva
soaring out in front on a single product and it is no surprise that the
Generics pack are waiting in the rear ready for the copaxone patents to
expire starting May 2014. However Biogen are backing the most winners
with a staggering $5.8 billion worth of business.
#1 Glaterimer acetate Teva $4.3 billion
#2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Showing posts with label Ampyra. Show all posts
Showing posts with label Ampyra. Show all posts
Friday, May 16
Wednesday, May 14
Monday, May 12
Tuesday's News for Neurologists: Here's 256 New Studies from 10/1 to Tuesday 10/29:
Neuropsychological, balance and mobility risk factors for falls in people with multiple sclerosis: a prospective cohort study.
Menopause in multiple sclerosis: therapeutic considerations.
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Neuropsychological, balance and mobility risk factors for falls in people with multiple sclerosis: a prospective cohort study.
Aerobic exercise increases hippocampal volume and improves memory in multiple sclerosis: Preliminary findings.
Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis.
MOST NEUROLOGISTS IN SCOTLAND DO NOT USE THE MCDONALD 2010 CRITERIA TO DIAGNOSE MULTIPLE SCLEROSIS.
sorry: this post was late due to technical problems! Friday's news will be posted at our normal time: midnight
Thursday's News for Neurologists: Here's 208 New Studies from 10/1 to Thursday 10/24:
Results confirm a favourable effect on relapses as pregnancy proceeds, and an early postpartum peak. Pre-conception DMT exposure and low ARR were independently protective against postpartum relapse. This novel finding could provide clinicians with a strategy to minimise postpartum relapse risk in women with MS planning pregnancy.
Copaxone (Glatiramer acetate) treatment effects on gene expression in monocytes of multiple sclerosis patients.
Overall, the observed gene regulatory effects of GA on monocytes were modest and not stable over time. However, our study revealed several genes that are worthy of investigation in future studies on the molecular mechanisms of GA therapy.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Most MS patients initiating DMT started on platform therapy. Natalizumab initiators tended to stay on index therapy, have fewer treatment gaps, and switch less than platform initiators in the 2 years after treatment initiation. Switching between platform therapies is common despite evidence that MS patients on platform therapy may benefit from switching to natalizumab.
[Cavitary lesions in multiple sclerosis: Multicenter study on twenty patients.]
MS patients with large cavitary lesions seem to represent a MS subgroup, predominantly women, with relatively late disease onset, predominantly primary-progressive type, relatively high EDSS scores, and severe cognitive dysfunction.
Results confirm a favourable effect on relapses as pregnancy proceeds, and an early postpartum peak. Pre-conception DMT exposure and low ARR were independently protective against postpartum relapse. This novel finding could provide clinicians with a strategy to minimise postpartum relapse risk in women with MS planning pregnancy.
Younger age, female sex, and high number of awakenings and arousals are
predictive of fatigue in sleep-disordered patients. Further
investigations are needed to find the pathophysiological explanation for
these relationships.
Overall, the observed gene regulatory effects of GA on monocytes were modest and not stable over time. However, our study revealed several genes that are worthy of investigation in future studies on the molecular mechanisms of GA therapy.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Most MS patients initiating DMT started on platform therapy. Natalizumab initiators tended to stay on index therapy, have fewer treatment gaps, and switch less than platform initiators in the 2 years after treatment initiation. Switching between platform therapies is common despite evidence that MS patients on platform therapy may benefit from switching to natalizumab.
[Cavitary lesions in multiple sclerosis: Multicenter study on twenty patients.]
MS patients with large cavitary lesions seem to represent a MS subgroup, predominantly women, with relatively late disease onset, predominantly primary-progressive type, relatively high EDSS scores, and severe cognitive dysfunction.
Wednesday's News for Neurologists: Here's 198 New Studies from 10/1 to Wednesday 10/23:
Comparative effectiveness of GILENYA (fingolimod) versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Curr Med Res Opin. 2013 Oct 1. [Epub ahead of print]Abstract Objective: Disease-modifying therapies, such as fingolimod, interferon (IFN) and glatiramer acetate (GA), have differing effects on relapse rates in patients with multiple sclerosis (MS), but little is known about the real-world differences in relapse rates with these treatments. This retrospective study assessed relapse rates in patients with active MS initiating fingolimod, IFN or GA therapy in a real-world setting. Methods: Using administrative claims data from the US PharMetrics Plus database, we identified previously treated and untreated patients with MS who initiated fingolimod, IFN or GA treatment between 1 October 2010 and 31 March 2011 and had experienced a relapse in the previous year. A claims-based algorithm was used to identify relapses over the persistence period in patients with 540 days of post-index continuous enrolment. A logistic regression model assessed the probability of having at least one relapse and a generalized linear model estimated differences in annualized relapse rates (ARRs). Results: The study enrolled 525 patients (fingolimod, n = 128; combined IFN/GA cohort, n = 397) of the 31,041 initially identified. Similar findings for fingolimod and IFN/GA were observed for the unadjusted proportion of patients experiencing relapses (31.3% vs. 34.0%, respectively; p = 0.5653) and ARRs (0.50 vs. 0.55, respectively) while persistent to treatment. After adjusting for baseline differences, fingolimod was associated with a 52% reduction in the probability of having a relapse (odds ratio, 0.48; 95% confidence interval [CI], 0.28-0.84; p = 0.0097) and a 50% reduction in ARR (rate ratio, 0.50; 95% CI, 0.34-0.75; p = 0.0006) compared with IFN/GA.
Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention.
The Treatment of Tremor.
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Myelin damage due to local quantitative abnormalities in normal prion levels: evidence from subacute combined degeneration and multiple sclerosis.
Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI.
Diffusion tensor magnetic resonance imaging may show abnormalities in the normal-appearing cervical spinal cord from patients with multiple sclerosis.
Multiple sclerosis in South America: month of birth in different latitudes does not seem to interfere with the prevalence or progression of the disease.
SATIVEX SPREADS TO ONE MORE COUNTRY: Sativex Cannabinoid oromucosal spray is for the treatment of spasticity due to Multiple Sclerosis. Sativex is approved as a treatment for MS spasticity in 22 countries
Prevalence of white matter lesions and stroke in children with migraine
FOR NEUROLOGISTS: 16 NEW STUDIES IN SATURDAY'S NEWS!
Plus 166 Studies from 10/1 to 10/16
Dalfampridine-ER was associated with short-term improvements in walking
speed and community participation, and sustained
improvements in walking endurance and
self-perceived impact of MS on walking for one year. Our study supports
the utility
of this medication in late MS.
ECTRIMS UPDATE #2: BIOGEN HAS 3 NEW MS TREATMENTS THEY ARE WORKING ON THAT ARE BEING PRESENTED AT ECTRIMS: THE WORLDWIDE MEETING OF NEUROLOGISTS:
Data at The ECTRIMS Meetings will be presented from across Biogen Idec’s portfolio, including:
Investigational medicines:
PLEGRIDY(pegylated interferon beta-1a): a potential new molecular entity for relapsing forms of MS in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. Pegylation offers a less-frequent dosing schedule.
DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells that can play a key role in MS without causing general immune cell depletion. DAC HYP is being developed under a collaboration agreement with AbbVie, Inc.
Anti-LINGO-1 (BIIB033): is the first candidate being investigated for its potential to repair neurons damaged by MS.
HERE'S MONDAY'S HEADLINES PLUS 169 MORE HEADLINES FOR YOU IN THE LAST 8 DAYS! MORE MS NEWS THAN ANY SITE IN THE WORLD!
Rituximab review
IMPAIRED DECISION-MAKING AND DIFFUSION ORIENTATIONAL COMPLEXITY IN PEOPLE WITH MULTIPLE SCLEROSIS
Vitamin d: shining a light on clinical and sex specific effects in multiple sclerosis?
The relation between Vitamin D status with fatigue and depressive symptoms of multiple sclerosis.
Multiple Sclerosis Research: Chinese Medicine..Getting DMT is ...
Mary Lahammer on living with multiple sclerosis: The feared disease a journalist lives with is no longer a death sentence.
Validity of the Dynamic Gait Index in People With Multiple Sclerosis
Longitudinal MR Imaging of Iron in Multiple Sclerosis: An Imaging Marker of Disease
Merck saw higher prices for its Rebif treatment for multiple sclerosis after it became available in a single-dose portable injector.
Sunday, May 11
Drug deal, R&D hike hit Biogen profit
Biogen Idec's profit for the second quarter was down significantly from the same period last year, due in part to the acquisition of a new experimental treatment for multiple sclerosis. The company included the acquisition as part of a 60-percent increase in year-on-year research and development costs.
The Cambridge, Mass.-based biopharmaceutical company reported net income of $144.9 million for the three months ending June 30, 2009, down from $208.1 million for the second quarter last year.
Revenue for the company was up for the second quarter, to $1.1 billion from $993 million during the second quarter of 2008. The increase was led by sales of the company’s two marketed treatments for Multiple Sclerosis, Avonex , which booked revenues of $591.2 million, up from $527.2 million and Tysabri, with sales of $187.6 million, up from $147.2 million. The increase in sales of Tysabri beat investors’ expectations.
Biogen paid $110 million to Accordia Therapeutics Inc. to licence the drug candidate Ampyra (Fampridine-SR).
Biogen’s (Nasdaq: BIIB) stock rose slightly on the news, during mid day trading on Thursday, to $47.06 from $46.67 at the previous close. .. story in the Boston Business Journal
The Cambridge, Mass.-based biopharmaceutical company reported net income of $144.9 million for the three months ending June 30, 2009, down from $208.1 million for the second quarter last year.
Revenue for the company was up for the second quarter, to $1.1 billion from $993 million during the second quarter of 2008. The increase was led by sales of the company’s two marketed treatments for Multiple Sclerosis, Avonex , which booked revenues of $591.2 million, up from $527.2 million and Tysabri, with sales of $187.6 million, up from $147.2 million. The increase in sales of Tysabri beat investors’ expectations.
Biogen paid $110 million to Accordia Therapeutics Inc. to licence the drug candidate Ampyra (Fampridine-SR).
Biogen’s (Nasdaq: BIIB) stock rose slightly on the news, during mid day trading on Thursday, to $47.06 from $46.67 at the previous close. .. story in the Boston Business Journal
FDA SETBACK FOR NEW ORAL DRUG: AMPYRA! As with most actions, there is a reaction elsewhere. Biogen Idec (TYSABRI) shares are up!
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is taking it right on the chin this morning. The company announced that it has received a “refuse to file letter” from the FDA regarding its New Drug Application for AMPRYA (Fampridine-SR). Unfortunately, this is supposed to be for a novel therapy being developed to improve walking ability in people with multiple sclerosis.The FDA raised “format issues” regarding the electronic submission, and it also requested that some of the data in the application be reformatted and that some additional supporting information be included in the filing. The good news is that the FDA did not request or recommend additional clinical or other studies.
Acorda’s CEO said it plans to address the issues raised in the FDA letter. He also noted that the company believes Fampridine-SR “is potentially an important, first in class treatment option for people suffering with MS.”
The company plans to request a meeting with FDA as soon as possible to discuss its comments on the NDA filing.
As with most actions, there is a reaction elsewhere. Biogen Idec Inc. (NASDAQ: BIIB) is the TYSABRI play for MS, and its shares are up by 0.8% at $52.95 this morning. These treatments may be a bit different in the fight against MS, and TYSABRI has had its own PML issues that has arguably kept the drug from being more widely used.
Acorda was expected to see total company revenues of about $60 million in 2009 and about $137 million in 2010. It is a safe bet that this filing acceptance may push back at least some of the expected revenue. The company had revenue of $47.8 million in 2008 and $39.4 million in 2007. Shares are down 18% at $20.50 in early trading on almost 4-times volume. Its 52-week trading range is $14.42 to $35.65..........................story in 24/7 Wall St.
Subscribe to:
Posts (Atom)